Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

NCT05290155 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

T Lymphoblastic Leukemia/Lymphoma
T-cell Acute Lymphoblastic Leukemia
Peripheral T Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Anaplastic Large Cell Lymphoma

Interventions

DRUG: anti-CD7 CAR-T cells

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine